Panel: Gene Editing and Intellectual Property: A Useful Mix? – 3/08/2019
Gene-editing technologies offer substantial promise in treating disease, but their use raises important ethical and public health questions about how these innovations should be applied and regulated. Different groups have also sought to patent these technologies. What are the most recent controversies in this area and how should we approach resolving them?
A light lunch will be provided. This event is free and open to the public, but space is limited and registration is required. Please note that attendees will need to show ID in order to enter the venue.
George Church, PhD, professor of genetics, Harvard Medical School
Jeantine Lunshof, PhD, research scientist-ethicist, MIT Media Lab and visiting fellow in genetics, Center for Bioethics, Harvard Medical School
Jacob S. Sherkow, JD, professor of law, Innovation Center for Law and Technology, New York Law School
The Health Policy and Bioethics Consortia is a monthly series that convenes two international experts from different fields or vantage points to discuss how biomedical innovation and health care delivery are affected by various ethical norms, laws, and regulations.
They are organized by the Harvard Medical School Center for Bioethics and the Program on Regulation, Therapeutics, and Law (PORTAL) at Brigham and Women’s Hospital, in collaboration with the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. Support provided by the Oswald DeN. Cammann Fund at Harvard University.